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CASE PRESENTATION
A 65-year-old woman presented with decreased 
vision in both eyes of 2 months’ duration. She 
reported no history of systemic disorders. 
Visual acuity (VA) was 20/200 in her right and 
20/400 in her left eye. Slit lamp examination 
was unremarkable and intraocular pressure was 
normal. On fundus examination, an elevated 
lesion was noted in the macula in both eyes.
Figures show color fundus (Fig. 1), infrared, 
and autofluorescence (AF) images (Fig. 2), as 
well as fluorescein angiography (FA) (Fig. 3 to 
5) and optical coherence tomography (OCT) 
images (Fig. 6 and 7) at presentation. Herein we 
present the views of four vitreoretinal specialists 
on the diagnosis and treatment of this patient.
Nasi Samiy, MD
This patient is a 65-year-old woman with 
reduced vision of 2 months’ duration, more 
severe in her left eye. Imaging studies are 
noteworthy for the presence of retinal pigment 
epithelium (RPE) detachments and subretinal 
fluid in both eyes (OU) on OCT (Figures 6 
and 7) and occult leakage on FA, OU (Figures 3 
to 5). The differential diagnosis would include 
wet age-related macular degeneration (AMD), 
central serous retinopathy (CSR), polypoidal 
choroidal vasculopathy (PCV), and posterior 
scleritis. Given the patient’s age and gender, I 
would approach this patient as a case of bilateral 
wet AMD until proven otherwise.
Figure 1. Color fundus photographs of the right and left 
eyes.
Figure 2. Infrared (upper) and autofluorescence (lower) 
images of both eyes.Challenging Case; Elevated Macular Lesions
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My first step would be to obtain an 
indocyanine green angiography (ICGA) which 
would help with the diagnosis of CSR and 
PCV. If ICGA is not available, I would start 
empiric treatment with an intravitreal anti-VEGF 
(vascular endothelial growth factor) agent.
One issue is whether to treat both eyes in 
the same session or on separate days. Concerns 
for endophthalmitis deter me from treating 
both eyes on the same day. The other potential 
complication of such management is RPE tear 
because of the height of the retinal pigment 
epithelial detachment (RPED). I would certainly 
discuss this possibility with the patient prior 
to initiating therapy.
CSR tends to occur in a younger age group 
but may also present in older subjects. Based 
on OCT and FA findings, it may be difficult 
to distinguish CSR from an occult choroidal 
neovascular membrane (CNVM). Furthermore, 
the classic “smokestack” finding on FA is seen 
in only 15% of patients with CSR. One helpful 
finding is relatively good vision despite the 
presence of significant subretinal fluid and 
RPED. However, poor vision, as in this patient, 
does not preclude a diagnosis of CSR. ICGA 
can show a more diffuse involvement of the 
choriocapillaris, with multiple distinct areas 
of RPED. In this particular patient, it would 
be helpful to ascertain recent steroid use. The 
presence of blood would have been helpful in 
that it rules out CSR and makes a diagnosis of 
wet AMD or PCV more likely.
ICGA could also be helpful for determining 
PCV as the etiology. The most helpful finding 
would be a lattice-like network of fine vessels 
at the choriocapillaris with bulging ends. 
These areas would correspond to areas of 
serosanguineous RPEDs. My treatment of choice 
for PCV is photodynamic therapy (PDT).
A retinal angiomatous proliferation (RAP) 
lesion is part of the spectrum of wet type AMD. 
RAP begins as an intraretinal neovascularization 
that evolves into a retinochoroidal anastomosis. 
One can often find intraretinal blood as well 
as RPED once an anastomotic connection 
between the RAP and the choriocapillaris has 
been made. Video ICGA can be particularly 
useful for delineating a fine choroidal capillary 
network with a feeder retinal arteriole and a 
draining retinal venule. My treatment of choice 
for RAP is the combination of an anti-VEGF 
agent and PDT.
One should also consider posterior scleritis 
as a possible diagnosis, however I doubt this 
to be the case for this patient because of the 
lack of pain and the absence of vitreous cells 
on examination.
Figure 3.  Fluorescein  angiograms  of  both  eyes  at  0:30 
(upper images) and 1:20 (lower images) time frames.
Figure 4.  Fluorescein  angiograms  of  both  eyes  at  2:10 
(upper images) and 2:30 (lower images) time frames.Challenging Case; Elevated Macular Lesions
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Zahra Alami Harandi, MD
This patient is a 65-year-old woman with 
decreased VA. In the fundus photograph 
of both eyes there is a cream–green colored 
lesion in the fovea, 4 to 5 disc diameters in 
size, with no hemorrhage or hard exudates 
but with some flecks (Fig. 1). Fundus AF 
displays faint hyper-autofluorescence of the 
lesion with areas of hypoautofluorescence 
(Fig. 2) within it. FA, in the early phase, shows 
central hypofluorescence with surrounding 
hyperfluorescence (Fig. 3). In the late phase, the 
hyperfluorescence becomes more intense and 
larger (Figures 4 and 5). There is vascularized 
RPED in both eyes on OCT images (Figures 6 
and 7). According to these findings, the most 
probable diagnosis is occult choroidal CNVM 
type I, a form of wet AMD.
Patients with neovascular AMD usually 
present with distortion or loss of central 
vision. On biomicroscopic examination there 
is usually serous or hemorrhagic detachment 
of the neurosensory retina and/or RPE with 
Figure 5.  Fluorescein  angiograms  of  both  eyes  at  3:10 
(upper images), 5:30 (middle images), and 7:10 (lower 
images) time frames.
Figure 6.  Optical  coherence  tomography  scans  of  the 
right eye with different radial scan orientations.Challenging Case; Elevated Macular Lesions
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or without hard exudation. Drusen and RPE 
changes are often present in the affected or 
fellow eye. Occult CNVM is divided into two 
types: (1) fibrovascular RPED (type I), and (2) 
late leakage of undetermined source (type II). 
The combination of CNVM and serous RPED 
has been termed vascularized RPED (V-RPED) 
and consists of sub-RPE neovascularization 
associated with a serous RPED.
FA remains, to date, the gold standard 
for establishing the diagnosis of exudative 
AMD, and is also required to determine the 
location, type, size, and degree of activity of 
the exudative lesion. In fibrovascular RPED, 
FA shows hyperfluorescence especially 1 
to 2 minutes after dye injection, beneath an 
irregular RPE with either well- or poorly-
defined boundaries, and persistent staining 
or late leakage.
In wet AMD, ICGA is often needed to 
confirm occult CNVM and the diagnosis of 
RAP and idiopathic PCV. ICGA is also superior 
for identifying the vascularized and serous 
component of V-RPED, as the serous component 
of an RPED is hypofluorescent while the vascular 
component is hyperfluorescent.
AF imaging provides information on RPE 
condition and indirectly, the photoreceptors. 
In cases of occult CNVM, multiple foci of low 
AF signals are commonly seen at the site of 
the lesions which represent small areas of RPE 
loss. Alternatively more irregular patterns of 
AF may be present which are followed by 
growth of a CNVM. AF imaging is useful for 
following the behaviour of the CNVM and the 
status of the RPE following treatment. It may 
help to predict visual outcomes after treatment. 
It was recently demonstrated that intact foveal 
AF is associated with better visual outcomes 
after anti-VEGF therapy. OCT can be used to 
determine the presence of sub- or intraretinal 
fluid, and may be useful in the follow up of 
patients after treatment.
The differential diagnoses of occult 
CNVM include vitelliform foveomacular 
dystrophy, chronic CSR, and choroidal tumors. 
Foveomacular dystrophy can mimic occult 
CNVM, however, the high intensity AF signal 
corresponding to the yellow deposits seen in 
this condition is not observed in AMD.
In the management of vascularized 
RPED, the efficacy of current treatment 
options is limited. Studies have shown that 
PDT and intravitreal triamcinolone acetonide 
(IVTA) administration do not effectively 
treat fibrovascular RPED. In a retrospective 
analysis, Chen et al reported on the use of 
intravitreal bevacizumab (IVB) in eyes with 
refractory fibrovascular RPED without any 
classical components which had previously 
received intravitreal pegaptanib sodium 
Figure 7. Optical coherence tomography scans of the left 
eye with different radial scan orientations.Challenging Case; Elevated Macular Lesions
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injections, thermal laser, PDT, or IVTA. This 
study suggested that bevacizumab may be 
a good first-line treatment for fibrovascular 
RPEDs. Interestingly, OCT images showed 
near-complete resolution of intraretinal and 
subretinal fluid, without a significant change 
in the height or area of the RPED itself. 
Furthermore, patients with these positive 
OCT changes had an improvement in vision, 
even without resolution of the RPED. It seems 
that improvement in vision is attributable to 
reduction in retinal edema, despite the lack of 
change in RPED size.
RPE  tears  are  known  to  develop 
spontaneously, as well as after conventional 
laser therapy, PDT, and anti-VEGF therapy. The 
most likely mechanism of RPE tear is mechanical 
contraction of the CNVM underneath the RPED. 
In RPE tear, foveal sparing and continued 
suppression of neovascular activity appear to 
contribute to visual preservation. Some patients 
experience improved or preserved vision with 
additional anti-VEGF therapy despite the RPE 
tear.
In conclusion I would recommend IVB 
administration for this particular patient despite 
the risk of inducing RPE tears.
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Masoud Naseripour, MD
Based on the provided information, this 65-year-
old woman demonstrates bilateral RPED 
associated with occult CNVM in the context 
of exudative AMD.
Although RPED may be associated with 
different chorioretinal diseases, including 
CSR, malignant hypertension, and choroidal 
inflammatory diseases such as the Vogt-
Koyanagi-Harada syndrome, the most common 
condition is AMD. The literature shows that 
up to 10% of all patients with AMD present 
with RPED. The pathogenesis of RPED and 
its clinical subtypes are beyond the scope of 
this case presentation, however causes of this 
entity include: stage II and III RAP, PCV, and 
a marginally situated occult CNVM.
Clinical signs suggesting the presence of a 
CNVM underlying an RPED include: subretinal 
fluid, lipid exudates, presence of hemorrhage, 
and chorioretinal folds. Fundus photography of 
both eyes in this patient shows bilateral serous 
RPED surrounded by an orange pigment ring, 
a possible indicator of chronicity, in the left 
fundus (Fig. 1).
AF imaging would be of great value for 
evaluating the integrity of the outer retina and 
assessing therapeutic interventions for exudative 
AMD in the era of anti-VEGF treatment. 
Small foci of reduced AF signals observed in 
both AF frames could be compatible with an 
occult CNVM (Fig. 2). The different quality 
of AF images between the eyes may be due to 
several factors including focusing, intensity 
of flashes, etc.
Regarding infrared (IR) frames, although 
occult CNVM shows poorly demarcated areas of 
scattered IR increase, the presence of associated 
lesions such as fibrin coagulates, drusen and 
RPE alterations may change the appearance of 
IR frames. The appearance of RPED on IR is 
determined by its shape, melanin content, and 
composition of sub-RPE fluid. Furthermore, the 
focus plane of scanning laser ophthalmoscopy 
(SLO) can affect the appearance of RPED. A 
dark core on the IR frame of the left eye shows 
that SLO has been focused deep to Bruch’s 
membrane, in contrast to the right eye IR Challenging Case; Elevated Macular Lesions
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frame, in which the presence of a bright spot 
indicates that the focal plane is near the apex of 
the serous detachment and that light has been 
scattered by the RPE (Fig. 2). Nevertheless, 
higher turbidity of sub-RPE fluid in the left 
eye cannot be ruled out.
FA shows pinpoint areas of speckled 
hyperfluorescence (more evident in the right 
eye) in the early phase (Fig. 3) followed by larger 
areas of hyperfluorescence at the margin of the 
lesion in late phase angiograms, particularly 
in the right eye (Figures 4 and 5). The source 
of leakage cannot be discerned from earlier 
phase FA. In such a case, ICGA is particularly 
useful for delineation of occult CNVM, and 
sometimes the condition may be reclassified 
into well-defined or classic CNVM. Several 
studies have confirmed the superiority of ICGA 
for detecting CNVM in patients with exudative 
AMD associated with RPED.
Simultaneous IR (Fig. 2) and OCT images 
(Figures 6 and 7) of the patient show RPEDs 
with hyporeflective spaces at the base in 
both eyes, associated with a small amount of 
subretinal fluid at the margin of the RPED in 
some frames. Although the increased noise of 
OCT images has decreased their resolution, 
the presence of small hyperreflective dots with 
thickening and breaks in the RPE represents 
CNVM, particularly at the margin of the RPEDs.
When interpreting OCT images in patients 
with RPED and neovascular AMD, one must 
keep in mind that RPED goes beyond the area 
of obvious hyperfluorescence on FA and this 
may cause some discrepancy between FA and 
OCT imaging.
Because  of  the  limited  options  for 
treatment of AMD patients with occult CNVM 
associated with RPED and severe vision loss, 
and the possibility of serious postoperative 
complications such as RPE tear, the management 
of these patients remains controversial.
The incidence of RPE tear in different 
studies ranges from 1.8% to 27%, these include 
natural history studies and reports on eyes 
undergoing different treatment modalities. 
As suggested by different studies, the natural 
course of patients with RPED and neovascular 
AMD is characterized by progressive visual 
loss. Over time, more fibrovascular tissue 
associated with chorioretinal atrophy develops 
and ultimately results in a fibrotic disciform 
scar. This process can be accelerated by RPE 
tears and subretinal hemorrhage. In addition, 
in such patients, the second eye is frequently 
involved (such as this patient) and a bilateral 
disciform macular scar often develops as the 
disease progresses.
Most authors believe that despite the 
risk of post-intervention visual loss, a high 
rate of stabilization in VA and morphological 
changes can be achieved with current treatment 
modalities, including PDT and intravitreal 
injection of anti-VEGF agents and/or steroids. 
Although all available therapeutic procedures 
have not yet been compared in a large 
randomized clinical trial, combination therapies 
such as intravitreal anti-VEGF with steroids or 
PDT, as well as PDT with IVTA, may be more 
effective than monotherapy for eyes with RPED 
associated with CNVM.
Identifying eyes at risk of RPE tear before 
initiating any treatment is very important. These 
include patients with advanced age, a large 
irregular vascularized RPED on FA (uneven 
filling) and/or a large and elevated RPED on 
OCT, presence of small areas of RPE thinning 
or small holes along the margins of the RPED, 
and vitreomacular traction on OCT.
In my opinion, in this particular case, a 
bilateral intravitreal injection of bevacizumab 
plus dexamethasone or triamcinolone 2 to 3 
weeks apart (to see if any possible RPE tear 
will develop in the first eye) could be a good 
and cost-effective option. If no post-treatment 
complications arise, multiple intravitreal 
injections should be considered.
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The fundus photographs of this 65-year-old 
woman demonstrate the presence of a well-
demarcated RPED involving the macula in 
both eyes (Fig. 1). Early (Fig. 3) and late 
phase FA images (Figures 4 and 5) show 
RPE window defects around the RPED with 
minimal leakage, suggesting the disease has 
a chronic nature. Fundus AF imaging shows 
multifocal and localized areas of reduced 
autofluorescence in the central macula (Fig. 
2). These findings are nonspecific and may 
represent abnormal metabolism of RPE cells. 
In the paracentral macula, AF shows mildy 
increased autofluorescence which may be 
associated with a previous episode of exudative 
neurosensory retinal detachment. Spectral 
domain OCT images in both eyes confirm 
the presence of RPED and also demonstrate 
mild intraretinal thickening and subretinal 
fluid accumulation (Figures 6 and 7). OCT 
images in the left eye, demonstrate a localized 
hyperreflective area at the level of the RPE nasal 
to the RPED which may represent a CNVM 
or deposition of abnormal material such as 
protein or vitelliform substances (Fig. 7). In 
view of the absence of hyperfluorescence on 
FA and the lack of increased autofluorescence 
at the corresponding location, the material is 
more likely to be fibrinous protein material.
RPED can be classified into four subtypes 
including serous RPED, fibrovascular RPED, 
hemorrhagic RPED, and drusenoid RPED. 
Common causes of RPED include AMD, PCV, 
and CSR. In patients with RPED, additional 
assessment with ICGA would be very useful 
to detect the presence of CNVM associated 
with neovascular AMD or polypoidal lesions 
in patients with PCV. Moreover, ICGA can 
provide better evaluation of the choroidal 
circulation in order to detect dilated choroidal 
vessels and choroidal hyperpermeability which 
are commonly seen in patients with CSR.
In this patient, since OCT showed the 
presence of RPED associated with subretinal 
fluid and macular thickening, intravitreal 
injections of anti-VEGF agents such as 
ranibizumab or bevacizumab might be useful 
to improve vision by reducing RPED and 
subretinal fluid. My routine practice is to inject 
three loading doses of an anti-VEGF agent at 
monthly intervals and perform serial OCT 
imaging to assess the treatment response. Studies 
have demonstrated that anti-VEGF therapy is 
effective in treating serous RPED associated with 
neovascular AMD. If the treatment response 
to initial anti-VEGF therapy is poor, ICGA is 
strongly recommended, as the disease might 
be caused by PCV, and combination therapy 
using PDT with verteporfin and intravitreal 
anti-VEGF agents may be useful for such cases. 
In cases of serous RPED associated with CSR, 
PDT using standard or half-dose verteporfin has 
been demonstrated to be useful; such treatment 
can reduce RPED size and improve vision.
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